eCQM Title | Inappropriately Broad Empiric Antibiotic Selection for Hospitalized Patients with Uncomplicated Community-Acquired Pneumonia |
||
---|---|---|---|
CMS ID | eCQM Version Number | Draft based on 0.0.000 | |
CBE Number | Not Applicable | GUID | e793af10-03f2-4a68-9c69-a15c6b3effcb |
Measurement Period | January 1, 2024 through December 31, 2024 | ||
Measure Steward | University of Utah | ||
Measure Developer | University of Utah | ||
Endorsed By | None | ||
Description |
The Inappropriately Broad Empiric Antibiotic Selection for Hospitalized Patients with Uncomplicated Community-Acquired Pneumonia is a process measure to quantify inappropriately broad empiric antibiotic use in adult hospitalized adults with uncomplicated community-acquired pneumonia. Inappropriately broad antibiotic use is defined as any antibiotic therapy targeting methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa in patients without risk factors for one of those organisms. The measure will be calculated using electronic health record (EHR) data and is intended for use at the facility level for both quality improvement and pay-for-performance. |
||
Copyright |
None |
||
Disclaimer |
None |
||
Measure Scoring | Proportion | ||
Measure Type | Process | ||
Stratification |
None |
||
Risk Adjustment |
|
||
Rate Aggregation |
|
||
Rationale |
The overall objective of this electronic clinical quality measure is to quantify inappropriately broad empiric antibiotic use in adult hospitalized adults with uncomplicated community-acquired pneumonia (CAP). Here, we defined “inappropriately broad” as any antibiotic therapy targeting methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa in patients without risk factors for one of those organisms. Antibiotic overuse is a national and international public health emergency with antibiotic resistant infections estimated to directly cause 1.27 million deaths globally and indirectly contribute to 4.95 million deaths. [1] National studies by the Centers for Disease Control and Prevention (CDC) estimate that up to 50% of hospitalized patients receive antibiotic therapy, most commonly for pneumonia, and that up to 40% of antibiotic prescribing could be improved. [2] Pneumonia is not only the most common reason for inpatient antibiotic use but also the most common infectious cause of mortality in the US resulting in approximately 1.4 million emergency department visits, 740 000 hospitalizations, 41 000 deaths, and $7.7 billion in inpatient costs each year in the US. [3-5] Adverse consequences of unnecessarily broad empiric therapy include an increased adjusted risk of death, kidney injury, and serious secondary infections. [6-8] How measure will improve quality of care? By establishing a standardized process to assess inappropriately broad empiric antibiotic use for CAP, a larger proportion of patients will potentially receive appropriate care consistent with the 2019 ATS/IDSA CAP national guidelines. [9] Appropriateness of antibiotic therapy for pneumonia is a priority for numerous federal organizations–including the CDC, The Joint Commission, and Centers for Medicare and Medicaid Services–and is not currently captured in typical quality improvement measures. For example, NHSN antimicrobial use (AU) measures focus on quantifying antibiotic use and comparing to expected values, with no assessment of appropriateness of empiric therapy. Notably, the NHSN AU initiative could be augmented with an eCQM to assess inappropriately broad empiric antibiotic selection for CAP. What are the benefits or improvements in quality envisioned by this measure? Inappropriately broad empiric therapy for CAP is common. A recent report on 8,286 non-ICU hospitalized CAP patients from 67 Michigan hospitals (assessed using the chart review measure from which our eCQM was adapted) showed that 2,215 (26.7%) received inappropriately broad empiric treatment (i.e., anti-MRSA or anti-PSA coverage in patients eligible for standard CAP coverage per ATS/IDSA guidelines). [10] Compared to patients who received standard CAP antibiotic treatment, patients receiving inappropriately broad antibiotics had higher 30-day readmissions, more transfers to ICU and antibiotic-associated adverse events, and longer hospitalizations. [10] Similarly, a retrospective analysis of 88,605 patients with CAP across the Veterans Health Administration health care system found that adding empirical anti-MRSA therapy (compared to standard CAP therapy) was associated with an increased adjusted risk of death, kidney injury, and secondary infections (C. difficile, vancomycin-resistant Enterococcus infection, and resistant gram-negative rod infections). [7] Given that up to 90% of prescribed broad spectrum antibiotic therapy is non-guideline concordant, [7,10] there is substantial potential benefit to patients and the US by reducing inappropriately broad empiric antibiotic selection. National surveillance of drug-related adverse events estimated that even a small reduction in unnecessary antibiotic use could significantly decrease the direct risks of drug-related adverse events in individual patients. [11] Thus, our guideline-based measure has the potential to improve patient care for a large number of patients hospitalized with CAP across the US. |
||
Clinical Recommendation Statement |
Joint ATS/IDSA clinical guidelines recommend not prescribing empiric anti-MRSA or anti-Pseudomonal therapy in uncomplicated CAP patients without risk factors for MRSA or Pseudomonas aeruginosa. |
||
Improvement Notation |
Decreased score indicates improvement |
||
Reference |
Reference Type: Citation Reference Text: '1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. Feb 12 2022;399(10325):629-655. doi:10.1016/s0140-6736(21)02724-0' |
||
Reference |
Reference Type: Citation Reference Text: '10. Gandhi T, Petty L, Vaughn V, et al. Risk Factors and outcomes associated with inappropriate empiric broad-spectrum antibiotic use in hospitalized patients with community-acquired pneumonia. Antimicrobial Stewardship & Healthcare Epidemiology. 2023;3(S2):s31-s32. doi:10.1017/ash.2023.258' |
||
Reference |
Reference Type: Citation Reference Text: '11. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis. Sep 15 2008;47(6):735-43. doi:10.1086/591126' |
||
Reference |
Reference Type: Citation Reference Text: '2. Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morbidity and mortality weekly report. Mar 7 2014;63(9):194-200.' |
||
Reference |
Reference Type: Citation Reference Text: '3. McDermott KW, Roemer M. Most Frequent Principal Diagnoses for Inpatient Stays in U.S. Hospitals, 2018. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Healthcare Research and Quality (US); 2006.' |
||
Reference |
Reference Type: Citation Reference Text: '4. Sterrantino C, Trifirò G, Lapi F, et al. Burden of community-acquired pneumonia in Italian general practice. Eur Respir J. Dec 2013;42(6):1739-42. doi:10.1183/09031936.00128713' |
||
Reference |
Reference Type: Citation Reference Text: '5. Partouche H, Lepoutre A, Vaure CBD, Poisson T, Toubiana L, Gilberg S. Incidence of all-cause adult community-acquired pneumonia in primary care settings in France. Med Mal Infect. Sep 2018;48(6):389-395. doi:10.1016/j.medmal.2018.02.012' |
||
Reference |
Reference Type: Citation Reference Text: '6. Branch-Elliman W, O’Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of Duration and Type of Surgical Prophylaxis With Antimicrobial-Associated Adverse Events. JAMA Surgery. 2019;154(7):590-598. doi:10.1001/jamasurg.2019.0569' |
||
Reference |
Reference Type: Citation Reference Text: '7. Jones BE, Ying J, Stevens V, et al. Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Intern Med. Apr 1 2020;180(4):552-560. doi:10.1001/jamainternmed.2019.7495' |
||
Reference |
Reference Type: Citation Reference Text: '8. Attridge RT, Frei CR, Restrepo MI, et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur Respir J. Oct 2011;38(4):878-87. doi:10.1183/09031936.00141110' |
||
Reference |
Reference Type: Citation Reference Text: '9. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. Oct 1 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST' |
||
Definition |
None |
||
Guidance |
This is a facility-level process eCQM to quantify the percentage of inappropriately broad empiric antibiotic use in adult medical patients hospitalized with uncomplicated community-acquired pneumonia (CAP). Here, we defined “inappropriately broad” as any antibiotic therapy targeting methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa in patients without risk factors for one of those organisms. Better performance is indicated by a lower score. |
||
Transmission Format |
TBD |
||
Initial Population |
Adult patients diagnosed with Community Acquired Pneumonia receiving standard care. |
||
Denominator |
Adult patients with an inpatient non-ICU hospitalization in which the discharge diagnosis includes pneumonia or sepsis AND respiratory failure (RF) who received a respiratory antibiotic within 48 hours of hospitalization, received chest imaging within +/- 3 days of the hospital encounter, were not transferred from another hospital, and do not have a concurrent infection. Restrict to patients without risk factors for methicillin resistant Staphylococcus aureus (MRSA) or Pseudomonas aeruginosa. |
||
Denominator Exclusions |
Exclude complex CAP patients with: mechanical ventilation in first 48 hours of hospitalization, ANC<500 cells/uL, cystic fibrosis, bronchiectasis, HIV, tracheostomy, transplant in prior year, hematologic malignancy, or pulmonary complication (empyema, lung abscess, necrotizing pneumona). Exclude cases in which there are risk factors present for Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PsA), including a positive respiratory culture for either organism in the prior year or severe pneumonia with prior hospitalization with IV antibiotic in the past 3 months. |
||
Numerator |
From the denominator population, identify who received empiric (hosptial day 1 or 2) antibiotics targeting MRSA or Pseudomonas |
||
Numerator Exclusions |
None |
||
Denominator Exceptions |
None |
||
Supplemental Data Elements |
For every patient evaluated by this measure also identify payer, race, ethnicity and sex. |
"Qualifying CAP Encounter for Patient with Appropriate Age"
"Initial Population"
"Complex CAP Encounter" union "Risk Factors for MRSA/PSA"
"Inappropriately Broad Empiric Antibiotic Selection"
None
None
None
["Encounter, Performed": "Encounter Inpatient"] Encounter with ["Laboratory Test, Performed": "Blood Urea Nitrogen"] BUN such that BUN.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and BUN.result as Quantity >= 20 'mg/dL'
["Encounter, Performed": "Encounter Inpatient"] Encounter where exists (["Laboratory Test, Performed": "Complete Blood Count (with Diff)"] CellCount where CellCount.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and exists CellCount.components Component where Component.code = "Platelets [#/volume] in Blood" and Component.result is not null and Component.result as Quantity < 100000 '{Cells}/uL')
"Relevant Comorbidities" union "Neutropenia" union "History of Transplant"
["Encounter, Performed": "Encounter Inpatient"] Encounter with Encounter.diagnoses ConcurrentDx such that ConcurrentDx.code in "CAP Concurrent Infections"
["Encounter, Performed": "Encounter Inpatient"] Encounter with ["Patient Characteristic Expired": "Dead (finding)"] Deceased such that Deceased.expiredDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours]
["Encounter, Performed": "Encounter Inpatient"] Encounter with ["Physical Exam, Performed": "Oxygen Saturation in Blood"] OxygenSat such that OxygenSat.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and OxygenSat.result as Quantity < 90 '%'
"Initial Population"
"Complex CAP Encounter" union "Risk Factors for MRSA/PSA"
"Deceased in 48 Hours" union "ICU Admission" union "Transfer In" union "Concurrent Infection"
["Encounter, Performed": "Encounter Inpatient"] Encounter with ["Physical Exam, Performed": "Inhaled oxygen flow rate"] Inhalation such that Inhalation.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and Inhalation.result as Quantity >= 5 'L/min'
["Encounter, Performed": "Encounter Inpatient"] Encounter with ["Physical Exam, Performed": "Respiratory Rate"] RespRate such that RespRate.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and RespRate.result as Quantity > 30 '{breaths}/min'
["Encounter, Performed": "Encounter Inpatient"] InpatientEncounter with ["Diagnostic Study, Performed": "Chest Imaging for Pneumonia Grouping Definition"] ChestImaging such that ChestImaging.authorDatetime during Interval [start of InpatientEncounter.relevantPeriod -72 hours, end of InpatientEncounter.relevantPeriod + 72 hours] and ChestImaging.authorDatetime during day of "Measurement Period"
"Qualifying CAP Encounter" QCAPEncounter with ["Procedure, Performed": "Major Transplant"] Transplant such that Transplant.relevantPeriod ends during day of Interval[start of QCAPEncounter.relevantPeriod - 365 days, start of QCAPEncounter.relevantPeriod]
["Encounter, Performed": "Encounter Inpatient"] Encounter where exists Encounter.facilityLocations Location where Location.code in "Intensive Care Unit" and Location.locationPeriod starts during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours]
"MDRO Antibiotics" union "IV Vancomycin"
"Qualifying CAP Encounter for Patient with Appropriate Age"
"Qualifying CAP Encounter" QCAPEncounter with ["Medication, Administered": "vancomycin"] Vanc such that Vanc.route in "Intravenous Medication Route"
["Encounter, Performed": "Encounter Inpatient"] Encounter where exists (["Laboratory Test, Performed": "Complete Blood Count (with Diff)"] CellCount where CellCount.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and exists CellCount.components Component where Component.code = "Leukocytes [#/volume] in Blood" and Component.result is not null and Component.result as Quantity < 4000 '{Cells}/uL')
["Encounter, Performed": "Encounter Inpatient"] Encounter with ["Physical Exam, Performed": "Body Temperature"] BodyTemp such that BodyTemp.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and BodyTemp.result as Quantity < 36 'Cel' or BodyTemp.result as Quantity < 96.8 '[degF]'
["Encounter, Performed": "Encounter Inpatient"] Encounter with ["Physical Exam, Performed": "Systolic Blood Pressure"] SystolicBP such that SystolicBP.relevantDatetime during Interval[start of Encounter.relevantPeriod, start of Encounter.relevantPeriod + 48 hours] and SystolicBP.result as Quantity < 80 'mm[Hg]'
"Qualifying CAP Encounter" QCAPEncounter with ["Medication, Administered": "Broad Spectrum Antibiotics for MDRO"] MDROabx such that MDROabx.relevantPeriod overlaps Interval[start of QCAPEncounter.relevantPeriod, start of QCAPEncounter.relevantPeriod + 48 hours]
"Qualifying CAP Encounter" QCAPEncounter where exists (["Laboratory Test, Performed": "Complete Blood Count (with Diff)"] BloodTest where exists BloodTest.components Component where Component.code = "Neutrophils [#/volume] in Blood" and Component.result is not null and Component.result as Quantity < 500 '{Cells}/uL')
"Inappropriately Broad Empiric Antibiotic Selection"
exists ("Qualifying CAP Encounter" QCAPEncounter where( exists(["Encounter, Performed": "Encounter Inpatient"] PriorHospitalization where PriorHospitalization.relevantPeriod overlaps Interval[start of QCAPEncounter.relevantPeriod - 3 months, start of QCAPEncounter.relevantPeriod] and exists ["Medication, Administered": "Antibiotic Usage for CAP Diagnosis"] Antibiotic where Antibiotic.authorDatetime during Interval[start of QCAPEncounter.relevantPeriod - 3 months, start of QCAPEncounter.relevantPeriod] and Antibiotic.route in "Intravenous Medication Route")))
"Qualifying Encounter" QEncounter where exists (QEncounter.diagnoses Diagnosis where Diagnosis.code in "CAP, Sepsis, Respiratory Failure Diagnostic")
"Qualifying CAP Encounter" QCAPEncounter where QCAPEncounter.relevantPeriod ends during day of "Measurement Period" and AgeInYearsAt(date from start of QCAPEncounter.relevantPeriod) >= 18
["Encounter, Performed": "Encounter Inpatient"] QCAPEncounter where exists (["Medication, Administered": "Antibiotic Usage for CAP Diagnosis"] Antibiotic where Antibiotic.authorDatetime during Interval[start of QCAPEncounter.relevantPeriod, start of QCAPEncounter.relevantPeriod + 48 hours]) and exists "Encounter with Chest Imaging during Hospitalization" ChestImagingEnc where ChestImagingEnc.id = QCAPEncounter.id and not exists "Disqualifying Encounter Elements" dqEncounter where dqEncounter.id = QCAPEncounter.id
"Qualifying CAP Encounter" QCAPEncounter with QCAPEncounter.diagnoses EncounterDiagnoses such that EncounterDiagnoses.code in "Comorbidities Indicated with CAP" or EncounterDiagnoses.code = "Human immunodeficiency virus [HIV] disease" or EncounterDiagnoses.code = "Patient immunocompromised (finding)"
"Secondary Infection" union "Severe CAP with Prior Hospitalization"
["Patient Characteristic Ethnicity": "Ethnicity"]
["Patient Characteristic Payer": "Payer Type"]
["Patient Characteristic Race": "Race"]
["Patient Characteristic Sex": "ONC Administrative Sex"]
"Qualifying CAP Encounter" QCAPEncounter with ["Laboratory Test, Performed": "Bacteria identified in Specimen by Respiratory culture"] RespCulture such that RespCulture.authorDatetime during Interval[start of QCAPEncounter.relevantPeriod - 365 days, start of QCAPEncounter.relevantPeriod] and RespCulture.result.code in "Pseudomonas aeruginosa (Organism or Substance in Lab Results)" or RespCulture.result.code in "MRSA (Disorders (SNOMED)"
"Qualifying CAP Encounter" QCAPEncounter where ( (if exists ("Elevated Respiration" ER where ER.id = QCAPEncounter.id) then 1 else 0) + (if exists ("Elevated Inhaled Oxygen" EIO where EIO.id = QCAPEncounter.id) then 1 else 0) + (if exists ("Decreased Oxygen Saturation" DOS where DOS.id = QCAPEncounter.id) then 1 else 0) + (if exists ("Leukopenia" LKP where LKP.id = QCAPEncounter.id) then 1 else 0) + (if exists ("Abnormal Platelet" AP where AP.id = QCAPEncounter.id) then 1 else 0) + (if exists ("Abnormal BUN" ABUN where ABUN.id = QCAPEncounter.id) then 1 else 0) + (if exists ("Low Body Temp" LBT where LBT.id = QCAPEncounter.id) then 1 else 0) + (if exists ("Low SBP" LSBP where LSBP.id = QCAPEncounter.id) then 1 else 0) ) >= 2 and "Prior Hospitalization with IV Antibiotic" is true
["Encounter, Performed": "Encounter Inpatient"] Encounter where exists ["Procedure, Performed": "Hospital admission, transfer from other hospital or health care facility (procedure)"] TransferIn
["Patient Characteristic Ethnicity": "Ethnicity"]
["Patient Characteristic Payer": "Payer Type"]
["Patient Characteristic Race": "Race"]
["Patient Characteristic Sex": "ONC Administrative Sex"]
Measure Set |
None |
---|